Prolia (denosumab) / Amgen, BeOne Medicines, Daiichi Sankyo - LARVOL DELTA

Mapping a Decade of Osteoporosis and Fracture Research: A Bibliometric Analysis (2015-2025). (PubMed, J Bone Metab) - "Global osteoporosis research demonstrates sustained productivity but declining collaboration and limited thematic diversification. Strengthening international networks, supporting underrepresented regions, and expanding focus to preventive and non-pharmacological strategies are essential for equitable and impactful progress."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Decoding Chronic Charcot Arthropathy: Molecular Mechanisms, Predictive Biomarkers, and Emerging Therapies. (PubMed, JB JS Open Access) - "» Current management relies primarily on mechanical interventions (accommodative footwear, bracing, surgical reconstruction for unbraceable deformities), but emerging molecular therapies targeting RANKL (denosumab), pro-inflammatory cytokines (IL-17 inhibitors), and Wnt pathway (romosozumab) show promise for disease modification. » Integrated risk stratification models combining genetic risk scores, serum biomarkers (RANKL/OPG ratio, vitamin D levels), and clinical factors can identify high-risk individuals (AUC 0.89), enabling targeted preventive interventions including vitamin D supplementation, prophylactic off-loading, and potentially pharmacological prevention."

Biomarker • Journal • Review • Diabetic Neuropathy • Infectious Disease • Inflammation • Metabolic Disorders • Pain • Rheumatology • IL17A • TNFRSF11B

Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations. (PubMed, Drugs Aging) - "Careful consideration must be given to the selection of antidiabetic medications, avoiding agents known to harm bone (e.g., thiazolidinediones) and preferring those with neutral or potentially beneficial skeletal effects (e.g., metformin, dipeptidyl peptidase-4 inhibitors [DPP-4i], glucagon-like peptide-1 receptor agonists [GLP-1 RAs]). Osteoporosis pharmacotherapies, including antiresorptive (bisphosphonates, denosumab) and anabolic agents (teriparatide, abaloparatide, romosozumab), appear effective in patients with diabetes largely on the basis of post hoc analyses and observational data, although evidence specific to this population remains limited. Integrating geriatric principles, such as assessing frailty and polypharmacy, is essential for optimizing care and improving outcomes for older adults with diabetes and bone fragility."

Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Reported Patterns and Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated with Novel Antineoplastic Therapies: A Retrospective Pharmacovigilance Analysis (AAD 2026) - "Introduction: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe, life-threatening drug reaction traditionally linked to anticonvulsants and allopurinol...Positive signals for DRESS were observed with several drugs, including imatinib, vemurafenib, thalidomide, brentuximab vedotin, and temozolomide. In contrast, drugs like nivolumab, rituximab, and denosumab showed negative signals... Our findings describe an emerging association of DRESS syndrome with novel antineoplastic therapies. The varied risk of DRESS across agents within the same class suggests that it is not necessarily a class-wide hypersensitivity. This highlights the need for increased clinician awareness to aid early recognition and prompt drug withdrawal to improve patient outcomes."

Adverse events • Retrospective data • Eosinophilia • Immunology

DENOSUMAB REDUCES ACUTE RENAL ALLOGRAFT REJECTION RISK COMPARED TO BISPHOSPHONATES: A TARGET TRIAL EMULATION (ISN-WCN 2026) - No abstract available

Transplant Rejection

LONG-TERM EXPERIENCE TREATING OSTEOPOROSIS WITH DENOSUMAB IN HEMODIALYSIS PATIENTS (ISN-WCN 2026) - No abstract available

Clinical • Osteoporosis • Renal Disease • Rheumatology

COMPARATIVE EFFECTIVENESS OF BISPHOSPHONATES AND DENOSUMAB FOR FRACTURE PREVENTION IN CHRONIC KIDNEY DISEASE: A REAL-WORLD NEW-USER COHORT STUDY (ISN-WCN 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Chronic Kidney Disease • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease

APPLICATION OF DENOSUMAB FOR OSTEOPOROSIS IN DIALYSIS PATIENTS (ISN-WCN 2026) - No abstract available

Clinical • Osteoporosis • Rheumatology

RECURRENT SEVERE HYPERCALCEMIA IN TUBERCULOUS PLEURITIS:SUCCESSFUL STEROID SPARING MANAGEMENT WITH DENOSUMAB IN ADVANCED CHRONIC KIDNEY DISEASE (ISN-WCN 2026) - No abstract available

Metastases • Chronic Kidney Disease • Endocrine Disorders • Metabolic Disorders • Nephrology • Renal Disease

mRNA profile to predict platin sensitivity in NSCLC: A translational analysis of the ETOP/EORTC SPLENDOUR trial (ELCC 2026) - "Background Cisplatin and carboplatin are standard therapy in non-small cell lung cancer (NSCLC), but efficacy varies...The Platin-DRP's clinical relevance in advanced NSCLC was evaluated in this retrospective-prospective analysis (PRoBE study design), in a cohort from the randomized phase III SPLENDOUR trial (UIN: researchregistry11317).Methods SPLENDOUR randomized 514 advanced NSCLC patients 1:1 to platinum chemotherapy ± denosumab...In the absence of validated predictive biomarkers for cis- and carboplatin, these results suggest that DRP may offer guidance in both clinical trials and practice. Further validation studies are ongoing, including the predictive role for immunotherapy plus chemotherapy."

IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

SETTING EVIDENCE STANDARDS BEFORE SETTING INTERNATIONAL PRICE BENCHMARKS: INSIGHTS FROM EX-U.S. G7 HEALTH TECHNOLOGY ASSESSMENTS ON TOP-SPENDING U.S. MEDICARE PART B BIOLOGICS (ISPOR 2026) - "health technology assessments (HTA) for top-spending U.S. Medicare Part B biologics. Using the Medicare Part B Drug Spending Dashboard (2023), the top-spending biologics—aflibercept, denosumab, daratumumab, nivolumab, and pembrolizumab—were identified. Inconsistent CER rigor and sparse PRO use across ex-U.S. G7 countries show the risk of referencing foreign prices without scrutinizing evidence. U.S."

Medicare • Reimbursement • US reimbursement

Annual Endocrine Practice Journal Symposium (AACE 2026) - "Alberto Piasentier on bisphosphonates and denosumab and vertebral fractures in prostate cancer patients; Dr. Daniel Slack on choice of hormone assay to monitor feminizing gender-affirming hormone therapy; and Dr. Ana-Maria Chindris on parathyroid hormone-guided calcium and calcitriol supplementation protocol for hypocalcemia."

Endocrine Disorders • Genito-urinary Cancer • Musculoskeletal Diseases • Prostate Cancer • Solid Tumor • PIAS4

The association between short-term denosumab use and the risk of sub-trochanteric and diaphyseal fractures among patients with osteoporosis (AACE 2026) - "Using a large real-world cohort, we found that short-term denosumab use was not associated with a higher risk of subtrochanteric or diaphyseal femur fractures compared with bisphosphonate use."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Evolution of BMD and bone turnover markers after denosumab discontinuation with zoledronic acid in patients with spinal cord injury-induced osteoporosis (EULAR 2026) - No abstract available

Clinical • CNS Disorders • Orthopedics • Osteoporosis • Rheumatology

Effect of denosumab on implant survival following total hip and knee arthroplasty in osteoarthritis patients: a registry-based data linkage study (EULAR 2026) - No abstract available

Clinical • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Romosozumab versus denosumab in glucocorticoid-induced osteoporosis: an extended observation of a randomized controlled trial at 48 months (EULAR 2026) - No abstract available

Clinical • Osteoporosis • Rheumatology

Preventable Life-Threatening Severe Hypocalcemia: The Importance of Medication Reconciliation (SCCM 2026) - "Her pantoprazole was switched to famotidine. While severe hypocalcemia from denosumab use is relatively rare, the presence of additional risk factors can significantly increase its likelihood, most notably, CKD, PPI usage, vitamin D deficiency, and low-normal calcium level at baseline, as each of these conditions impair either absorption or regulation of calcium, compounding the effect of denosumab. There are no current guidelines recommending earlier checks even in potentially higher risk patient population. This case highlight the importance of risk factors optimization includes vitamin D and calcium supplementation if needed and thorough medication reconciliation."

Breast Cancer • Chronic Kidney Disease • CNS Disorders • Endocrine Disorders • Epilepsy • Gastroenterology • Gastroesophageal Reflux Disease • Nephrology • Renal Disease • Solid Tumor

Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic mice. (PubMed, Front Endocrinol (Lausanne)) - "However, discontinued therapy after denosumab-zoledronate sequence, showed that the protective effects of zoledronate were not persistent. Our findings establish TgRANKL mice as a unique osteoporotic model for investigating the mechanisms driving denosumab rebound and testing sequential antiresorptive strategies."

Journal • Preclinical • Musculoskeletal Diseases • Obesity • Orthopedics • Osteoporosis • Rheumatology • TNFSF11

Multiple Myeloma: Diagnosis and Treatment. (PubMed, Am Fam Physician) - "Adjunctive care includes bisphosphonates or denosumab and venous thromboembolism prophylaxis. Family physicians play a crucial role in the patient's multidisciplinary team for addressing psychosocial needs, identifying relapse or recurrence, and managing comorbidities."

Journal • Review • Cardiovascular • Endocrine Disorders • Fatigue • Hematological Disorders • Hematological Malignancies • Metabolic Disorders • Multiple Myeloma • Musculoskeletal Pain • Oncology • Pain • Renal Disease • Transplantation • Venous Thromboembolism

Comparison of traditional and new treatments for fibrous dysplasia: a systematic review and meta-analysis. (PubMed, Osteoporos Int) - "Denosumab has shown promising results in recent years in terms of reducing the size and activity of fibrous dysplasia lesions and improving bone markers. Further research is needed to better prevent the serious side effects sometimes associated with this treatment."

Journal • Retrospective data • Review • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • Pain

AN ELECTRIFYING PRESENTATION OF MALIGNANCY-ASSOCIATED HYPERCALCEMIA: AFIB AND COMPLETE HEART BLOCK (ACC 2026) - "Our priority was correcting calcium with IV fluids, calcitonin, bisphosphonate, and denosumab... Malignancy-associated hypercalcemia can precipitate both atrial and nodal arrhythmias. Careful telemetry, thoughtful selection of rate control, and correction of underlying metabolic derangements are essential for safe management."

Acute Kidney Injury • Atrial Fibrillation • B Cell Lymphoma • Bladder Cancer • CNS Disorders • Colon Cancer • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Endocrine Disorders • Genetic Disorders • Genito-urinary Cancer • Heart Failure • Hematological Malignancies • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Oncology • Renal Disease • Solid Tumor • Urothelial Cancer

REVERSIBLE HYPOCALCEMIC CARDIOMYOPATHY PRECIPITATING HEART FAILURE AND REVEALING SEVERE TRIPLE-VESSEL CORONARY ARTERY DISEASE (ACC 2026) - "While CAD remains the predominant cause of HF, this case demonstrates that metabolic insults such as denosumab-induced hypocalcemia can precipitate reversible cardiomyopathy and uncover severe CAD. Calcium optimization before denosumab is critical to avoid this life-threatening but reversible complication."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Endocrine Disorders • Genito-urinary Cancer • Heart Failure • Prostate Cancer • Solid Tumor

Optimizing Denosumab Therapy in Rheumatic Diseases: Considerations for Disease Activity, Glucocorticoid Use, and Sequential Treatment. (PubMed, J Rheumatol) - No abstract available

Journal • Rheumatology

Anti-GBM disease secondary to ipilimumab/nivolumab immunotherapy (UKKW 2026) - "He had received four cycles of ipilimumab/nivolumab combination immunotherapy and had continued on nivolumab since, with denosumab being added for bone protection...However, his anti-GBM levels returned as 392 and he was treated with 3x pulses of daily 500mg IV methylprednisolone, PO cyclophosphamide 1.5mg/kg, and four cycles of plasma exchange...Proposed mechanisms include development of autoreactive CD4 T cells specific for α3NC1, and loss of self-tolerance mechanisms for the former, and invasive tumour growth causing exposure of the glomerular basement membrane for the latter. Frequent urinalysis on immunotherapy is required to allow for early biopsy to exclude rarer glomerulopathies."

Clear Cell Renal Cell Carcinoma • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Glioblastoma • Glomerulonephritis • Immunology • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • CD4

Keratin-Positive Giant Cell-Rich Tumor: Expanded Clinicopathologic Spectrum Including Tumors with Limited Keratin Expression and Intra-Articular Origin (USCAP 2026) - "Treatment included partial excision (3) followed by pexidartinib (1), denosumab (1) or radiation (1). We describe 6 KPGCT with previously unreported features including limited or absent keratin expression and intra-articular origin, expanding our evolving understanding of these recently described neoplasms."

Clinical • Giant Cell Tumor of Bone • Oncology • Tenosynovial Giant Cell Tumor • HMGA2 • NCOR2